# US 2012/0252048 A1 · Compositions comprising a dehalogenase substrate and a contrast agent and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252048 A1
- Document ID: US20120252048A1
- Status: Published application
- Kind: A1
- Application number: 13/450,217
- Filed: 2012-04-18
- Published: 2012-10-04
- Earliest claimed: 2003-01-31
- Assignees: Promega Corporation
- Inventors: Keith V. Wood; Dieter Klaubert; Georgyi V. Los; Robert F. Bulleit; Mark McDougall; Chad Zimprich
- Web page: https://patentgrep.com/patent/US20120252048A1

## CPC

- C12Q 1/34: involving hydrolase
- C07C 217/08: the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
- C07C 271/16: to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C07D 209/48: with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 311/78: Ring systems having three or more relevant rings
- C07D 311/82: Xanthenes
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 493/10: Spiro-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07F 5/022: {without C-boron linkages}
- C12N 9/14: Hydrolases (3)
- C12N 9/86: acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)}
- C12Y 308/01005: Haloalkane dehalogenase (3.8.1.5)
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- G01N 33/58: involving labelled substances (G01N33/53 takes precedence)
- Y10S 436/80: Fluorescent dyes, e.g. rhodamine
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.

## Claims

### Claim at position 1

1-109. (canceled)

### Claim 110

A compound of formula (I): R-linker-A-X, wherein R comprises a contrast agent, wherein the linker is a multiatom straight or branched chain including C, N, S and/or O and comprising no more than 30 carbon atoms, wherein A-X is a substrate for a dehalogenase, wherein A is (CH2)n and n=2-10, and wherein X is a halogen.

### Claim 111 (depends on 110)

The compound of claim 110, which is a substrate for a Rhodococcus dehalogenase.

### Claim 112 (depends on 110)

The compound of claim 110, wherein X is Cl or Br.

### Claim 113 (depends on 110)

The compound of claim 110, wherein the linker separates R and A by at least 11 atoms.

### Claim 114 (depends on 110)

The compound of claim 110, wherein the contrast agent in an MRI contrast agent.

### Claim 115 (depends on 114)

The compound of claim 114, wherein the MRI contrast agent comprises gadolinium.

### Claim 116 (depends on 114)

The compound of claim 114, wherein the MRI contrast agent comprises manganese.

### Claim 117 (depends on 114)

The compound of claim 114, wherein the MRI contrast agent comprises iron oxide.

### Claim 118 (depends on 110)

The compound of claim 110, wherein the contrast agent is separated from A-X by up to 500 angstroms.

### Claim 119 (depends on 110)

The compound of claim 110, wherein the linker comprises —C(O)NH(CH2CH2O)y, wherein y=2-8.

### Claim 120

A method for preparing a compound of formula R-Linker-A-X wherein the Linker comprises an amide bond comprising coupling a corresponding activated ester with a corresponding amine to provide the compound of formula R-Linker-A-X, wherein R comprises a contrast agent, wherein the linker is a multiatom straight or branched chain including C, N, S and/or O and comprising no more than 30 carbon atoms, wherein A-X is a substrate for a dehalogenase, wherein A is (CH2)n and n=2-10, and wherein X is a halogen.

### Claim 121 (depends on 120)

The method of claim 120, wherein the contrast agent comprises gadolinium.

### Claim 122 (depends on 120)

The method of claim 120, wherein the contrast agent comprises manganese.

### Claim 123 (depends on 120)

The method of claim 120, wherein the contrast agent comprises iron oxide.

### Claim 124 (depends on 120)

The method of claim 120, wherein the linker comprises —C(O)NH(CH2CH2O)y, wherein y=2-8.

### Claim 125

A compound of formula (I): R-linker-A-X, wherein R comprises a gadolinium-containing MRI contrast agent, wherein the linker is a multiatom straight or branched chain including C, N, S and/or O and comprising no more than 30 carbon atoms, wherein A-X is a substrate for a dehalogenase, wherein A is (CH2)n and n=2-10, and wherein X is a halogen.

### Claim 126 (depends on 125)

The compound of claim 125, which is a substrate for a Rhodococcus dehalogenase.

### Claim 127 (depends on 125)

The compound of claim 125, wherein X is Cl or Br.

### Claim 128

A compound of formula (I): R-linker-A-X, wherein R comprises a manganese-containing MRI contrast agent, wherein the linker is a multiatom straight or branched chain including C, N, S and/or O and comprising no more than 30 carbon atoms, wherein A-X is a substrate for a dehalogenase, wherein A is (CH2)n and n=2-10, and wherein X is a halogen.

### Claim 129 (depends on 128)

The compound of claim 128, which is a substrate for a Rhodococcus dehalogenase.

### Claim 130 (depends on 128)

The compound of claim 128, wherein X is Cl or Br.

### Claim 131

A method to label a cell, comprising:
contacting a cell comprising a mutant dehalogenase with a dehalogenase substrate which comprises a contrast agent,
wherein the mutant dehalogenase comprises at least one amino acid substitution relative to a corresponding wild-type dehalogenase, wherein at least one amino acid substitution results in the mutant dehalogenase forming a bond with the substrate which is more stable than the bond formed between the corresponding wild-type dehalogenase and the substrate, wherein at least one amino acid substitution in the mutant dehalogenase is a substitution at an amino acid residue in the corresponding wild-type dehalogenase that is associated with activating a water molecule which cleaves a bond formed between the corresponding wild-type dehalogenase and the substrate or at an amino acid residue in the corresponding wild-type dehalogenase that forms an ester intermediate with the substrate,
wherein the substrate is a compound of formula (I): R-linker-A-X, wherein R comprises the contrast agent, the linker is a multiatom straight or branched chain including C, N, S and/or O, wherein A-X is a substrate for a dehalogenase, wherein A is (CH2)n and n=2-10, and wherein X is a halogen.

### Claim 132 (depends on 131)

The method of claim 131, which is the substrate is a substrate for a Rhodococcus dehalogenase.

### Claim 133 (depends on 131)

The method of claim 131, wherein X is Cl or Br.

### Claim 134 (depends on 131)

The method of claim 131, wherein the contrast agent in an MRI contrast agent.

### Claim 135 (depends on 134)

The method of claim 134, wherein the MRI contrast agent comprises gadolinium.

### Claim 136 (depends on 134)

The method of claim 134, wherein the MRI contrast agent comprises manganese.

### Claim 137 (depends on 134)

The method of claim 134, wherein the contrast agent comprises iron oxide.

### Claim 138 (depends on 131)

The method of claim 131, wherein the linker comprises—C(O)NH(CH2CH2O)y, wherein y=2-8.

### Claim 139

A method to detect or determine the presence or amount of a mutant dehalogenase, comprising:
a) contacting a mutant dehalogenase with a dehalogenase substrate which comprises a contrast agent, wherein the mutant dehalogenase comprises at least one amino acid substitution relative to a corresponding wild-type dehalogenase, wherein the at least one amino acid substitution results in the mutant dehalogenase forming a bond with the substrate which is more stable than the bond formed between the corresponding wild-type dehalogenase and the substrate, wherein the at least one amino acid substitution in the mutant dehalogenase is a substitution at an amino acid residue in the corresponding wild-type dehalogenase that is associated with activating a water molecule which cleaves the bond formed between the corresponding wild-type dehalogenase and the substrate or at an amino acid residue in the corresponding wild-type dehalogenase that forms an ester intermediate with the substrate, wherein the substrate is a compound of formula (I): R-linker-A-X, wherein R comprises the contrast agent, the linker is a multiatom straight or branched chain including C, N, S and/or O, wherein A-X is a substrate for the dehalogenase, and X is a halogen; and
b) detecting or determining the presence or amount of the contrast agent, thereby detecting or determining the presence or amount of the mutant dehalogenase.

### Claim 140 (depends on 139)

The method of claim 139, which is the substrate is a substrate for a Rhodococcus dehalogenase.

### Claim 141 (depends on 139)

The method of claim 139, wherein X is Cl or Br.

### Claim 142 (depends on 139)

The method of claim 139, wherein the contrast agent in an MRI contrast agent.

### Claim 143 (depends on 142)

The method of claim 142, wherein the MRI contrast agent comprises gadolinium.

### Claim 144 (depends on 142)

The method of claim 142, wherein the MRI contrast agent comprises manganese.

### Claim 145 (depends on 142)

The method of claim 142, wherein the contrast agent comprises iron oxide.

### Claim 146 (depends on 139)

The method of claim 139, wherein the linker comprises —C(O)NH(CH2CH2O)y, wherein y=2-8.
